[ODP-181] Vaccine development against tuberculosis by using BCG-derived membrane vesicles
Background: Tuberculosis (TB), caused by the bacillus Mycobacterium tuberculosis, is the world’s leading infections disease. Bacillus Calmette-Guerin (BCG) is a sole efficient vaccine for prevention of TB. In present study, we tried vaccine development using BCG-derived membrane vesicles (BCG-MV).
Methods and Results: Six-week-old female BALB/c mice were immunized by BCG-MV twice with 3 weeks interval. Two weeks after second immunization, mice were sacrificed. Combination of BCG-MV and an adjuvant induced anti-BCG antibody production in serum, lung wash, nasal wash, saliva. Isolated splenocytes were stimulated by BCG-MV and cytokine production was assessed. Interferon gamma production was significantly increased in splenocytes from mice immunized by BCG-MV with the adjuvant.
Conclusion: BCG-MV could induce both humoral and cellular immunity against TB only when combined with the adjuvant.
Methods and Results: Six-week-old female BALB/c mice were immunized by BCG-MV twice with 3 weeks interval. Two weeks after second immunization, mice were sacrificed. Combination of BCG-MV and an adjuvant induced anti-BCG antibody production in serum, lung wash, nasal wash, saliva. Isolated splenocytes were stimulated by BCG-MV and cytokine production was assessed. Interferon gamma production was significantly increased in splenocytes from mice immunized by BCG-MV with the adjuvant.
Conclusion: BCG-MV could induce both humoral and cellular immunity against TB only when combined with the adjuvant.